Table I.
Association between Foxp3 expression and clinicopathological characteristics of patients with diffused large B-cell lymphoma.
| Foxp3 expression | |||||
|---|---|---|---|---|---|
| Clinicopathological characteristics | Number | High, n | Percentage | χ2 | P-value |
| Sex | |||||
| Male | 120 | 41 | 34.2 | 0.057 | 0.464 |
| Female | 81 | 29 | 35.8 | ||
| Age, years | |||||
| ≤60 | 123 | 41 | 33.3 | 0.192 | 0.386 |
| >60 | 77 | 28 | 36.4 | ||
| Diameter, cm | |||||
| ≤10 | 164 | 57 | 34.8 | 0.022 | 0.528 |
| >10 | 22 | 8 | 36.4 | ||
| Location | |||||
| Intranodular | 136 | 47 | 34.6 | 0.013 | 0.515 |
| Extranodular | 65 | 23 | 35.4 | ||
| Subtypes | |||||
| GCB | 105 | 29 | 27.6 | 5.857 | 0.012 |
| Non-GCB | 93 | 41 | 44.1 | ||
| IPI | |||||
| 0 | 104 | 28 | 26.9 | 5.857 | 0.012 |
| >0 | 82 | 36 | 43.9 | ||
| Performance state | |||||
| ≤2 score | 165 | 59 | 35.8 | 0.022 | 0.526 |
| >2 score | 32 | 11 | 34.4 | ||
| B symptom | |||||
| No | 99 | 37 | 37.4 | 0.294 | 0.347 |
| Yes | 98 | 33 | 33.7 | ||
| Clinical stage | |||||
| 1 and 2 | 112 | 33 | 29.5 | 3.453 | 0.045 |
| 3 and 4 | 75 | 32 | 42.7 | ||
| Extranodal sites | |||||
| ≤2 | 158 | 57 | 36.1 | 0.273 | 0.383 |
| >2 | 29 | 9 | 31.0 | ||
| LDH, U/l | |||||
| ≤240 | 103 | 32 | 31.1 | 1.141 | 0.181 |
| >240 | 83 | 32 | 38.6 | ||
| Therapeutic effect | |||||
| PR+CR | 90 | 31 | 34.4 | 4.488 | 0.032 |
| PD+SD | 20 | 12 | 60.0 | ||
| R-CHOP treatment | |||||
| No | 94 | 37 | 39.4 | 0.881 | 0.218 |
| Yes | 80 | 26 | 32.5 | ||
High expression was defined as moderate positive staining (++) and strong positive staining (+++) for Foxp3. GCB, germinal centre B-cell; Fox3P, forkhead/winged-helix protein 3; IPI, International Prognostic Index; LDH, lactate dehydrogenase; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; R-CHOP, rituxan, cyclophosphamide, adriamycin, vincristine, prednisone.